GlassScriptPhysician profile
Niyati Patel
NPI 1013285659
$1,358.19
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $46.20 · 2021: $90.69 · 2022: $475 · 2023: $166 · 2024: $78.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $238.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $199.06 | 2021-2023 | |
| Aerie Pharmaceuticals, INC. | $186.06 | 2019 | |
| Oyster Point Pharma, INC. | $185.19 | 2022 | |
| Biotissue Holdings INC. | $137.90 | 2023-2024 | |
| Alcon Vision LLC | $98.58 | 2020-2023 | Precision 1 |
| Allergan, INC. | $92.07 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $45.80 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $40.24 | 2019-2022 | |
| Shire North American Group INC | $31.14 | 2019 | |
| Bausch & Lomb Americas INC. | $21.38 | 2022 | |
| Sun Pharmaceutical Industries INC. | $19.80 | 2020 | |
| Eyevance Pharmaceuticals LLC | $19.67 | 2022 | |
| Novo Nordisk INC | $14.85 | 2020 | |
| Abbvie INC. | $14.36 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $13.17 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niyati Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.